Boehringer Ingelheim Biopharmaceuticals GmbH

Boehringer Ingelheim Biopharmaceuticals GmbH, operating as Boehringer Ingelheim BioXcellence™, is the dedicated contract manufacturing arm of Boehringer Ingelheim, a global pharmaceutical leader. With more than four decades of biotechnology expertise, BioXcellence™ has built a strong reputation as a world-class Contract Development and Manufacturing Organization (CDMO), supporting partners in the biopharmaceutical industry with reliable, scalable, and innovative solutions. The company’s global manufacturing network includes state-of-the-art facilities in the USA, Europe, and Asia, offering full-spectrum services in both mammalian cell culture and microbial fermentation. These capabilities cover the complete product lifecycle, from process development and clinical supply through to large-scale commercial production of biologics. Boehringer Ingelheim BioXcellence™ specializes in late-stage product development, providing flexible and customized solutions to meet complex regulatory requirements while ensuring the highest quality and safety standards. Their comprehensive service offering includes process and analytical development, GMP manufacturing, fill and finish, and lifecycle management. As a trusted partner to biotech innovators and large pharmaceutical companies alike, BioXcellence™ combines scientific expertise with global reach, enabling partners to bring biopharmaceutical therapies to patients faster and more efficiently. Their commitment to excellence, innovation, and patient health has positioned them as one of the most reliable and established CDMOs worldwide. By choosing Boehringer Ingelheim BioXcellence™, clients gain access to a legacy of biopharmaceutical excellence, a collaborative partnership model, and a proven track record of success in delivering safe, effective, and market-ready biologics.